Comparative Pharmacology
Head-to-head clinical analysis: GENTACIDIN versus NEOMYCIN SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GENTACIDIN versus NEOMYCIN SULFATE.
GENTACIDIN vs NEOMYCIN SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting protein synthesis and causing bacterial cell death by disrupting the cytoplasmic membrane.
5-7 mg/kg IV every 24 hours.
1-2 g orally 4 times daily (8-16 g/day) for hepatic encephalopathy or intraluminal infection; 0.5-1 g orally 4 times daily for preoperative bowel preparation.
None Documented
None Documented
2-3 hours in adults with normal renal function; extended to 24-48 hours in anuria or severe renal impairment, requiring dose adjustment.
2-3 hours (normal renal function); prolonged to 20-60 hours in anuria
Renal: 95-98% unchanged via glomerular filtration; biliary/fecal: <2%.
Renal (glomerular filtration) >90% unchanged; small amount biliary/fecal (<3%)
Category C
Category A/B
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic